A Living Tissue Bank of Patient-Derived Organoids From Glioma Tumors
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMaastricht Radiation Oncology
About this trial
There is a high medical need to improve treatment outcome for high-grade and low-grade glioma since no curative treatment is available. To achieve this goal, a broader understanding is needed of the causes of inter-and intratumoral heterogeneity; glioma dedifferentiation and invasion; the major determinants of malignancy and treatment failure in glioma patients. Patient-derived organoid (PDOs) of high-grade gliomas and low-grade gliomas will be used to identify the mechanisms that underlie this malignant behaviour and treatment resistance. This insight may be used to develop patient avatars to simultaneously test multiple new treatment modalities that are predictive for survival and quality of life of glioma patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
MRI diagnosis of low grade glioma (LGG) or high grade glioma (HGG)
Age 18 years or older
Patient is eligible for a resection of the tumor
Disqualifiers
Contra-inidication for neurosurgical resection of the tumor.
Incapacitated patient, unable to give informed consent.
Trial population
Patients who have an MRI lesion suspected for a low- or high grade glioma (newly diagnosed or recurrent), who are eligible for a resection of the tumor.
Trial design
Design model
Other
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
50 Participants
are grouped into 2 trial groupsGroup A: Low grade glioma patients
Group B: High grade glioma patients
Trial outcomes
Primary outcomes
1
Phenotypic, genetic, epigenetic proteomic and transcriptomic profile of the LGG/HGG PDOs
Phenotypic, genetic, epigenetic proteomic and transcriptomic profile of the LGG/HGG PDOs will be performed after establishing PDO and the data will be compared with the phenotypic, genetic, epigenetic, proteomic and transcriptomic profile of the parental tumor. DNA isolated from peripheral blood will be used as normal reference DNA for (epi)genetic profiling.
Time frame
Baseline tumor resection and blood samplingSponsors and contacts
Click on the lead sponsor to view all of their trials.
Maastricht Radiation Oncology
Lead sponsor
Maastricht University Medical Center
Collaborator
Zuyderland Medisch Centrum
Collaborator
Ziekenhuis Oost-Limburg
Collaborator
Source ClinicalTrials.gov